Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis.
COVID-19
KL-6
lung injury
prognosis
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
23
11
2020
revised:
29
12
2020
accepted:
08
01
2021
pubmed:
13
1
2021
medline:
20
3
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
To investigate the dynamic changes of Krebs von den Lungen-6 (KL-6) among patients with coronavirus disease 2019 (COVID-19) and the role of KL-6 as a noninvasive biomarker for predicting long-term lung injury, the clinical information and laboratory tests of 166 COVID-19 patients were collected, and a correlation analysis between KL-6 and other parameters was conducted. There were 17 (10.2%, 17/166) severe/critical and 149 (89.8%, 149/166) mild COVID-19 patients in our cohort. Serum KL-6 was significantly higher in severe/critical COVID-19 patients than in mild patients (median 898.0 vs. 451.2 U/ml, p < .001). KL-6 was next confirmed to be a sensitive and specific biomarker for distinguishing mild and severe/critical patients and correlate to computed tomography lung lesions areas. Serum KL-6 concentration during the follow-up period (>100 days postonset) was well correlated to those concentrations within 10 days postonset (Pearson r = .867, p < .001), indicating the prognostic value of KL-6 levels in predicting lung injury after discharge. Finally, elevated KL-6 was found to be significantly correlated to coagulation disorders, and T cells subsets dysfunctions. In summary, serum KL-6 is a biomarker for assessing COVID-19 severity and predicting the prognosis of lung injury of discharged patients.
Identifiants
pubmed: 33433006
doi: 10.1002/jmv.26793
pmc: PMC8013517
doi:
Substances chimiques
Biomarkers
0
MUC1 protein, human
0
Mucin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2505-2512Subventions
Organisme : Guangdong Provincial Department of Science and Technology Fund
ID : 2020B1111330002
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
J Med Virol. 2021 Feb;93(2):934-944
pubmed: 32706426
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
J Med Virol. 2021 Jan;93(1):158-160
pubmed: 32633842
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
J Rheumatol. 2000 May;27(5):1164-70
pubmed: 10813282
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Biomark Med. 2020 Jun;14(8):665-674
pubmed: 32613855
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Adv Ther. 2020 Jul;37(7):3033-3039
pubmed: 32504450
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Dermatol Ther. 2020 Nov;33(6):e14053
pubmed: 32700813
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Acad Radiol. 2020 May;27(5):603-608
pubmed: 32204987
Cell Res. 2020 Jun;30(6):541-543
pubmed: 32346074
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Arch Pathol Lab Med. 2020 Oct 1;144(10):1223-1229
pubmed: 32551814
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Chest. 1995 Aug;108(2):311-5
pubmed: 7634858
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
Lancet Haematol. 2020 Sep;7(9):e630-e632
pubmed: 32659213
Front Med (Lausanne). 2020 Oct 05;7:557453
pubmed: 33123541
Am J Respir Cell Mol Biol. 2013 Jun;48(6):742-8
pubmed: 23418343
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Rev Saude Publica. 2020;54:60
pubmed: 32491116
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
J Med Virol. 2021 Apr;93(4):2505-2512
pubmed: 33433006
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778